Rachel F. Tyndale
Department of Pharmacology and Toxicology
The University of Toronto
Toronto
ON M5S 1A8
Canada
Name/email consistency: high
- Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis. Wassenaar, C.A., Dong, Q., Amos, C.I., Spitz, M.R., Tyndale, R.F. Int. J. Mol. Sci (2013)
- Differential Effects of Nicotine Treatment and Ethanol Self-Administration on CYP2A6, CYP2B6 and Nicotine Pharmacokinetics in African Green Monkeys. Ferguson, C.S., Miksys, S., Palmour, R.M., Tyndale, R.F. J. Pharmacol. Exp. Ther. (2012)
- Independent and Combined Effects of Ethanol Self-Administration and Nicotine Treatment on Hepatic CYP2E1 in African Green Monkeys. Ferguson, C.S., Miksys, S., Palmour, R., Tyndale, R.F. Drug Metab. Dispos. (2011)
- Relationship Between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 Variation and Smoking Behaviors and Lung Cancer Risk. Wassenaar, C.A., Dong, Q., Wei, Q., Amos, C.I., Spitz, M.R., Tyndale, R.F. J. Natl. Cancer Inst. (2011)
- Genetics of alcohol and tobacco use in humans. Tyndale, R.F. Ann. Med. (2003)
- Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Tyndale, R.F., Sellers, E.M. Ther. Drug. Monit (2002)
- Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Tyndale, R.F., Sellers, E.M. Drug Metab. Dispos. (2001)
- Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Tyndale, R.F., Li, Y., Li, N.Y., Messina, E., Miksys, S., Sellers, E.M. Drug Metab. Dispos. (1999)
- A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Tyndale, R.F., Pianezza, M.L., Sellers, E.M. Nicotine Tob. Res. (1999)
- Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation. Tyndale, R.F., Bhave, S.V., Hoffmann, E., Hoffmann, P.L., Tabakoff, B., Tobin, A.J., Olsen, R.W. J. Pharmacol. Exp. Ther. (1997)
- Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Tyndale, R.F., Droll, K.P., Sellers, E.M. Pharmacogenetics (1997)